Radicle Clarity 24: A Study of Health and Wellness Products on Cognitive Function and Related Health Outcomes

Cognitive Function Clinical Trial

Official title:

Radicle Clarity™ 24: A Randomized, Double-Blind, Placebo-Controlled Direct-to-Consumer Study Assessing the Impact of Health and Wellness Products on Cognitive Function and Related Health Outcomes

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06294431
• Other study ID #: RADX-P-2406
• Status: Recruiting
• Phase: N/A
• Start date: February 22, 2024
• Est. completion date: October 2024

Study information

• Verified date: May 2024
• Source: Radicle Science
• Contact: Study Manager
• Phone: 760-281-3898
• Email: studymgmt[@]radiclescience.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A randomized, double-blind, placebo-controlled direct-to-consumer study of health and wellness products on cognitive function and related health outcomes

Description:

This is a randomized, double-blind, placebo-controlled study conducted with adult participants, residing in the United States.

Eligible participants will (1) endorse a desire for better concentration, (2) have the opportunity for meaningful improvement (at least 20%) in their primary health outcome, and (3) express acceptance in taking a product and not knowing its formulation until the end of the study.

Participants that report a known cardiac dysfunction, liver or kidney disease may be excluded. Participants that report a known contraindication or with well-established, significant safety concerns due to illness will be excluded. Heavy drinkers and those who report they are pregnant, trying to become pregnant, or breastfeeding will be excluded. Participants that report taking medications with a known contraindication or with well-established, significant safety concerns will be excluded.

Self-reported data are collected electronically from eligible participants for 7 weeks. Participant reports of health indicators will be collected at baseline, throughout the active period of study product use, and in a final survey. All study assessments will be electronic, there are no in-person visits or assessments for this real-world evidence study.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 1901
• Est. completion date: October 2024
• Est. primary completion date: July 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 21 Years to 105 Years

Eligibility

Inclusion Criteria:

• Adults, at least 21 years of age at the time of electronic consent, inclusive of all ethnicities, races, and gender identities. Assigned sex at birth will determine sex-specific recruitment and surveys (male vs female) employed, when needed

• Resides in the United States

• Endorses better concentration or cognitive function (fewer feelings of brain fog) as a primary desire

• Has the opportunity for at least 20% improvement in their primary health outcome

• Expresses a willingness to take a study product and not know the product identity (active or placebo) until the end of the study

Exclusion Criteria:

• Report being pregnant, trying to become pregnant, or breastfeeding

• Unable to provide a valid US shipping address and mobile phone number

• Reports current enrollment in another clinical trial

• Reports being a heavy drinker (defined as drinking 3 or more alcoholic beverages per day)

• Unable to read and understand English

• Reports a current and/or recent (up to 3 months ago) major illness and/or surgery that poses a known, significant safety lak

• Reports a diagnosis or cardiac dysfunction, liver or kidney disease that presents a known contraindication and/or a significant safety risk with any of the study product ingredients. NYHA (New York Heart Association) Class Ill or IV congestive heart failure, atrial fibrillation, uncontrolled arrhythmias, cirrhosis, end-stage liver disease, stage 3b or 4 chronic kidney disease, or kidney failure

• Reports taking medications that have a well-established moderate or severe interaction, posing a substantial safety risk with any of the study product ingredients. Anticoagulants, antihypertensives, anxiolytics, antidepressants, chemotherapy, immunotherapy, sedative hypnotics, seizure medications, medications that warn against grapefruit consumption, corticosteroids at doses greater than 5 mg per day, diabetic medications, oral anti-infectives (antibiotics, antifungals, antivirals) to treat an acute infection, antipsychotics, MAOls (monoamine oxidase inhibitors), or thyroid products

• Reports current use of the primary ingredient(s) and/or similar product(s) to the active study product(s)

• Lack of reliable daily access to the internet

Related Conditions & MeSH terms

• Cognitive Function

Intervention

Dietary Supplement:
• Placebo Control Form 1
Participants will use their Placebo Control Form 1 as directed for a period of 6 weeks.
• Clarity Active Study Product 1.1 Usage
Participants will use their Radicle Clarity Active Study Product 1.1 as directed for a period of 6 weeks.
• Placebo Control Form 2
Participants will use their Placebo Control Form 2 as directed for a period of 6 weeks.
• Clarity Active Study Product 2.1 Usage
Participants will use their Radicle Clarity Active Study Product 2.1 as directed for a period of 6 weeks.
• Placebo Control Form 3
Participants will use their Placebo Control Form 3 as directed for a period of 6 weeks.
• Clarity Active Study Product 3.1 Usage
Participants will use their Radicle Clarity Active Study Product 3.1 as directed for a period of 6 weeks.
• Clarity Active Study Product 3.2 Usage
Participants will use their Radicle Clarity Active Study Product 3.2 as directed for a period of 6 weeks.

Locations

Country	Name	City	State
United States	Radicle Science, Inc	Del Mar	California

Sponsors (1)

Lead Sponsor	Collaborator
Radicle Science

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Change in mood (emotional distress-depression)	Mean difference in mood score as assessed by PROMIS Depression 4A (scale 4-20; where higher scores correspond to more severe depression)	6 weeks
Other	Change in concentration of at-home (direct-to-consumer) specimen assays either saliva, blood or stool	Mean difference in specimen assays as surrogates and/or markers for health outcomes. (Optional; among consented participants only) Potentially include saliva (IgG, cytokines, DHEA-S, Estradiol, Progesterone, Testosterone, Cortisol, Melatonin, CRP) blood (1 drop) (Cortisol, Homocysteine, Ferritin, TSH, HbA1c, Insulin, Vitamin D, DHEA-S, Testosterone, Estradiol, FSH, Total Cholesterol, HDL, LDL, Triglycerides, ApoA1, ApoB). Stool (microbial diversity).	6 weeks
Primary	Change in cognitive function	Mean difference in cognition function score as assessed by Patient Reported Outcome Measurement System (PROMIS) Cognitive Function Short Form 8A (scale 8-40; where the higher scores correspond to greater cognitive function)	6 weeks
Secondary	Change in fatigue	Mean difference in fatigue score as assessed by PROMIS Fatigue 4A (scale 4-20; where higher scores correspond to more severe fatigue)	6 weeks
Secondary	Change in sleep-related impairment	Mean difference in sleep-related impairment score as assessed by PROMIS Sleep-Related Impairment 4A (scale 4-20; with higher scores corresponding to greater sleep-related impairment)	6 weeks
Secondary	Minimal clinical importance difference (MCID) in cognitive function	Likelihood of achieving a MCID in cognitive function, as measured by PROMIS Cognitive Function Short Form 8A (scale 8-40; where the higher scores correspond to greater cognitive function)	6 weeks

External Links

•   Radicle Science, Inc